{"DataElement":{"publicId":"5728047","version":"1","preferredName":"Unknown Hormone Replacement Therapy Pharmaceutical Formulation Taken Reason","preferredDefinition":"The explanation for why an unknown form of HRT was taken.","longName":"UNK_HRT_FORM_TKN_RSN","context":"ECOG-ACRIN","contextVersion":"1","DataElementConcept":{"publicId":"5727905","version":"1","preferredName":"Unknown Hormone Replacement Therapy Pharmaceutical Formulation Taken","preferredDefinition":"Not known, not observed, not recorded, or refused._Treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production._The composition of a dosage form, including the characteristics of its raw materials and the operations required to process it.Formulation factors include chemical nature of the drug (ester, salt, complex, etc), drug solubility in water and organic solvents, particle size and surface area, type of dosage form (solution, suspension, capsule, tablet) and the excipients and processes used in the manufacturing of the drug delivery systems. The design of optimal drug delivery systems is thus an important part of providing an effective therapeutic.Official formulations for approved agents are presented in such books as the National Formulary and US Pharmacopeia. Whereas at one time, these were detailed and almost recipe-like, more recent entries may be limited to specifying the formula and imposing a standard limit for the active agent._Having been accepted for some purpose; ingested as a medication.","longName":"5728046v1.0:2185700v1.0","context":"ECOG-ACRIN","contextVersion":"1","ObjectClass":{"publicId":"5728046","version":"1","preferredName":"Unknown Hormone Replacement Therapy Pharmaceutical Formulation","preferredDefinition":"Not known, not observed, not recorded, or refused.:Treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production.:The composition of a dosage form, including the characteristics of its raw materials and the operations required to process it.Formulation factors include chemical nature of the drug (ester, salt, complex, etc), drug solubility in water and organic solvents, particle size and surface area, type of dosage form (solution, suspension, capsule, tablet) and the excipients and processes used in the manufacturing of the drug delivery systems. The design of optimal drug delivery systems is thus an important part of providing an effective therapeutic.Official formulations for approved agents are presented in such books as the National Formulary and US Pharmacopeia. Whereas at one time, these were detailed and almost recipe-like, more recent entries may be limited to specifying the formula and imposing a standard limit for the active agent.","longName":"C17998:C15599:C42638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Unknown","conceptCode":"C17998","definition":"Not known, observed, recorded; or reported as unknown by the data contributor.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Hormone Replacement Therapy","conceptCode":"C15599","definition":"Treatment with estrogens or estrogen/progesterone after menopause or ovariectomy to prevent pathological effects of decreased estrogen production.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Pharmaceutical Formulation","conceptCode":"C42638","definition":"The composition of a dosage form, including the characteristics of its raw materials and the operations required to process it.Formulation factors include chemical nature of the drug (ester, salt, complex, etc), drug solubility in water and organic solvents, particle size and surface area, type of dosage form (solution, suspension, capsule, tablet) and the excipients and processes used in the manufacturing of the drug delivery systems. The design of optimal drug delivery systems is thus an important part of providing an effective therapeutic.Official formulations for approved agents are presented in such books as the National Formulary and US Pharmacopeia. Whereas at one time, these were detailed and almost recipe-like, more recent entries may be limited to specifying the formula and imposing a standard limit for the active agent.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BF351B5-5FB7-6BD7-E053-F662850ADB60","latestVersionIndicator":"Yes","beginDate":"2017-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-30","modifiedBy":"ONEDATA","dateModified":"2017-03-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2185700","version":"1","preferredName":"Taken","preferredDefinition":"Having accepted for some purpose; ingested as a medication.","longName":"C25701","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Taken","conceptCode":"C25701","definition":"Having been accepted for some purpose; ingested as a medication.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DD634685-0E93-0ECC-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-07-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2004-07-02","modifiedBy":"DATA_LOADER","dateModified":"2005-10-19","changeDescription":"Added Concept Code AA","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"ACRIN:American College of Radiology Imaging Network","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BF34045-0057-1617-E053-F662850A3041","latestVersionIndicator":"Yes","beginDate":"2017-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-30","modifiedBy":"TAYLORT","dateModified":"2018-11-14","changeDescription":"11/14/18 tt released/metrics report. 3/20/17 tt, EA1151.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"5270077","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"Reason","context":"DCP","contextVersion":"1","type":"Non-enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"255","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[],"ConceptualDomain":{"publicId":"2008556","version":"1","preferredName":"Assessment Results","preferredDefinition":"the results of evaluations of the patient and the patient's disease.","longName":"ASSESS_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2D08DE9-38BB-7208-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2240632","version":"1","preferredName":"Reason","preferredDefinition":"An explanation of the cause of some phenomenon or action.","longName":"C25638","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Reason","conceptCode":"C25638","definition":"An explanation of the cause of some phenomenon or action.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F9FA7953-8391-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-06-30","endDate":null,"createdBy":"PWEST","dateCreated":"2005-06-30","modifiedBy":"ONEDATA","dateModified":"2005-06-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"330E255F-7C45-6B7E-E050-BB89AD4313D1","latestVersionIndicator":"Yes","beginDate":"2016-05-17","endDate":null,"createdBy":"KNABLEJ","dateCreated":"2016-05-17","modifiedBy":"ZHANGWE","dateModified":"2016-07-08","changeDescription":"5/17/16 created for DCP","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"3314482","version":"1","longName":"Type of Category","context":"ECOG-ACRIN","ClassificationSchemeItems":[{"publicId":"10000277","version":"1","longName":"Eligibility","context":"ECOG-ACRIN"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"Form of hormone replacement t","type":"Preferred Question Text","description":"Form of hormone replacement therapy unknown- reason taken","url":null,"context":"ECOG-ACRIN"}],"origin":"ACRIN:American College of Radiology Imaging Network","workflowStatus":"RELEASED","registrationStatus":"Application","id":"4BF351B5-5FCF-6BD7-E053-F662850ADB60","latestVersionIndicator":"Yes","beginDate":"2017-03-30","endDate":null,"createdBy":"TAYLORT","dateCreated":"2017-03-30","modifiedBy":"TAYLORT","dateModified":"2018-11-14","changeDescription":"11/14/18 tt released/metrics report. 3/30/17 tt, EA1151","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}